Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00678210 · ClinicalTrials.gov registry record · Phase 2
Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 197
- Enrollment target
NCT00678210 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 197 participants.
The verdict
NCT00678210, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 197 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness and safety, over 12 weeks, of 3 dosing regimens of CP-690,550 for the treatment of adults with moderate to severe chronic plaque psoriasis.
Interventions
- DRUG Placebo
- DRUG CP-690,550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00678210
The ClinicalTrials.gov registry entry for NCT00678210 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00678210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00678210 about?
NCT00678210 is a clinical study titled "Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis". The purpose of this study is to determine the effectiveness and safety, over 12 weeks, of 3 dosing regimens of CP-690,550 for the treatment of adults with moderate to severe chronic plaque psoriasis.
What is the current status of trial NCT00678210?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 197 participants. The study started on 2008-07. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00678210?
The interventions under investigation include: Placebo (DRUG), CP-690,550 (DRUG).
Who is sponsoring clinical trial NCT00678210?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.